EUVIMEDEUVIMED entdecken
Crossref

Topical delivery of baricitinib-impregnated nanoemulgel: a promising platform for inhibition of JAK -STAT pathway for the effective management of atopic dermatitis

Shweta Nene, Geetanjali Devabattula, Ganesh Vambhurkar, Kamatham Pushpa Tryphena, Dharmendra Kumar Khatri, Chandraiah Godugu, Pankaj Kumar Singh, Saurabh Srivastava iD

Drug Delivery and Translational Research · 2025-06 · 15 (6) · 2200-2219

DOI: 10.1007/s13346-024-01732-5 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Delivery and Translational Research, online erschienen am 28.10.2024. Verfasst von Shweta Nene und 7 weiteren Autor:innen. Beteiligte Einrichtung: Pharmaceutical Innovation and Translational Research Lab (PITRL), Department of Pharmaceutics, National Institute of Pharmaceutical Education and Res…. Hauptthemen laut MEDLINE: Azetidines, Purines, Dermatitis, Atopic, Sulfonamides. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 41 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Baricitinib, an inhibitor of Janus kinase 1/2 receptors majorly involved in the dysregulation of immune responses in atopic dermatitis, is currently approved for managing atopic dermatitis in Europe. The delivery of baricitinib through oral route is associated to several adverse effects due to off-target effects. Therefore, the current study is aimed at formulation of baricitinib loaded nanoemulgel for evaluation of topical delivery potential in the treatment of atopic dermatitis. The baricitinib-loaded nanoemulsions (0.05 and 0.1% w/w) revealed an average globule size of 162.86 ± 0.37 and 173.66 ± 4.88 nm respectively with narrow PDI. The optimized batch of baricitinib nanoemulsion was converted to nanoemulgel by the addition of the mixture of gel bases SEPINEO™ DERM and SEPINEO™ P 600 along with propylene glycol, resulting in pseudoplastic shear thinning behaviour. The optimized nanoemulgels have shown prominent retention of baricitinib in the skin along with permeation. The skin distribution study of coumarin-6 loaded nanoemulgel demonstrated high fluorescence in the epidermal layer. The western blot analysis revealed significant inhibition of phosphorylated signal transducers and activators of transcriptions 1 (##p < 0.01) and 3 (#p < 0.05) by application of 0.05 and 0.1% baricitinib nanoemulgel. The baricitinib nanoemulgels have shown anti-inflammatory activity by significantly reducing expressions of various inflammatory markers. Histopathological analysis of skin tissues treated with baricitinib nanoemulgel has demonstrated a marked reduction in acanthosis, hyperkeratosis, and intact outer epidermis. These results supported the potential role of baricitinib-loaded nanoemulgel in reducing the inflammation and disease severity associated with atopic dermatitis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AzetidinesPurinesDermatitis, AtopicSulfonamidesPyrazolesNanoparticlesJanus Kinase InhibitorsAnimalsEmulsionsSignal TransductionSkinAdministration, CutaneousSkin AbsorptionGelsSTAT Transcription FactorsHumans

Stichwörter der Autor:innen

Atopic dermatitisBaricitinibHistopathologyNanoemulsionTopical delivery

Substanzen

baricitinibAzetidinesPurinesSulfonamidesEmulsionsPyrazolesJanus Kinase InhibitorsGelsSTAT Transcription Factors

Autor:innen und Institutionen

  • Pharmaceutical Innovation and Translational Research Lab (PITRL), Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad, India.
  • Department of Biological Sciences, National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad, India.
  • Pharmaceutical Innovation and Translational Research Lab (PITRL), Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad, India. saurabh@niperhyd.ac.in.
  • Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER), Balanagar, Hyderabad, Telangana, 500037, India. saurabh@niperhyd.ac.in.

ORCID-Profile: Saurabh Srivastava

Zitieren

APA

Nene, S., Devabattula, G., Vambhurkar, G., Tryphena, K. P., Khatri, D. K., Godugu, C., Singh, P. K., & Srivastava, S. (2025). Topical delivery of baricitinib-impregnated nanoemulgel: a promising platform for inhibition of JAK -STAT pathway for the effective management of atopic dermatitis. Drug Delivery and Translational Research, 15(6), 2200-2219. https://doi.org/10.1007/s13346-024-01732-5

Vancouver

Nene S, Devabattula G, Vambhurkar G, Tryphena KP, Khatri DK, Godugu C, et al. Topical delivery of baricitinib-impregnated nanoemulgel: a promising platform for inhibition of JAK -STAT pathway for the effective management of atopic dermatitis. Drug Delivery and Translational Research. 2025;15(6):2200-2219. doi:10.1007/s13346-024-01732-5

BibTeX
@article{Nene2025,
  author = {Nene, Shweta and Devabattula, Geetanjali and Vambhurkar, Ganesh and Tryphena, Kamatham Pushpa and Khatri, Dharmendra Kumar and Godugu, Chandraiah and Singh, Pankaj Kumar and Srivastava, Saurabh},
  title = {Topical delivery of baricitinib-impregnated nanoemulgel: a promising platform for inhibition of JAK -STAT pathway for the effective management of atopic dermatitis},
  journal = {Drug Delivery and Translational Research},
  year = {2025},
  volume = {15},
  number = {6},
  pages = {2200--2219},
  doi = {10.1007/s13346-024-01732-5}
}
Kostenlos starten →